Table 3.
Exposure (ever/never) to individual immunosuppressive and immunomodulatory agents throughout follow-up. IVIG: intravenous immunoglobulin; TNF: tumor-necrosis factor
| Medication Exposure (ever/never) |
Total N=51 |
Chronic N=42 |
Remission N=9 |
p-value |
|---|---|---|---|---|
| Methotrexate | 43% | 43% | 44% | 1.00 |
| Mycophenolate | 71% | 69% | 78% | 0.71 |
| Azathioprine | 51% | 50% | 56% | 1.00 |
| Rituximab | 31% | 38% | 0% | 0.04 |
| Hydroxychloroquine | 51% | 48% | 67% | 0.47 |
| IVIG | 45% | 45% | 44% | 1.00 |
| Corticosteroids | 94% | 95% | 89% | 0.45 |
| Tacrolimus | 18% | 19% | 11% | 1.00 |
| Cyclophosphamide | 6% | 2% | 22% | 0.08 |
| TNF inhibitor | 12% | 12% | 11% | 1.00 |